Cleveland Diagnostics and Quest Diagnostics Expand Access to Prostate Cancer Test
Cleveland Diagnostics announced an agreement with Quest Diagnostics to expand patient access to its novel prostate cancer test, IsoPSA.
Read MorePosted by Andy Lundin | Feb 13, 2023 | Prostate |
Cleveland Diagnostics announced an agreement with Quest Diagnostics to expand patient access to its novel prostate cancer test, IsoPSA.
Read MorePosted by Andy Lundin | Feb 10, 2023 | Prostate |
LynxDx is introducing a non-invasive, data-driven, urine prostate cancer screening test to guide clinical decisions for patients.
Read MorePosted by Andy Lundin | Feb 8, 2023 | Prostate |
Researchers at the University of East Anglia helped develop a blood test to detect prostate cancer with greater accuracy than current methods.
Read MorePosted by Andy Lundin | Feb 2, 2023 | Prostate |
Investigators found that the test was able to distinguish cancer localized to the prostate from cancer that spread to other parts of the body.
Read MorePosted by Andy Lundin | Dec 15, 2022 | Prostate |
Researchers pioneered and implemented a novel algorithm to provide genetic testing to patients with newly diagnosed prostate cancer.
Read More